Status:
COMPLETED
Clinicopathological Characteristics and Prognosis Analysis of Stage IB Non-small Cell Lung Cancer
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Stage IB Non-Small Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this observation study is to learn about clinicopathological characteristics and prognostic factors of stage IB NSCLC. The main question it aims to answer is wheather there is relationship...
Detailed Description
A total of 971 NSCLC patients with pathological stage IB resected by surgery (R0) from January 2016 to December 2020 at Zhongshan Hospital of Fudan University were reviewed. The primary endpoint is RF...
Eligibility Criteria
Inclusion
- It was confirmed by histopathology as primary non-small cell lung cancer, and the pathological type was LUSC or LUAD;
- According to the 8th edition of TNM clinical staging standards, it is determined as IB stage
- No treatment was performed for the primary lesion of lung cancer before surgery;
- No history of other malignant tumors before surgery;
- Detailed clinical and pathological information, complete survival data, and no missing follow-up data.
Exclusion
- The postoperative histopathological types include non-scale and non adenocarcinoma, such as lung adenosquamous cell carcinoma, large cell lung cancer, or lung sarcomatoid carcinoma;
- Multiple lesion staging surgery;
- History of merging with other malignant tumors
- Having preoperative treatment;
- Missing follow-up information.
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
971 Patients enrolled
Trial Details
Trial ID
NCT05979623
Start Date
January 1 2016
End Date
December 1 2022
Last Update
August 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
180 Fenglin Road
Shanghai, China, 200032